CAJ | 학술논문

目的探讨小剂量阿糖胞苷和去甲氧柔红霉素联合粒细胞集落刺激因子(G-CSF)组成的IAG预激方案治疗急性髓系白血病(AML)的疗效和患者不良反应.方法回顾性分析25例AML患者在采用IAG预激方案诱导治疗1个疗程后的临床效果.IAG方案:去甲氧柔红霉素5 mg,静脉滴注,隔天1次,共7～8次;阿糖胞苷每12 h 10 mg/m2,皮下注射,第1天至第14天;G-CSF每天200 μg/m2,皮下注射,用药前一天至第14天.结果化疗后总有效率80.0％(20/25),完全缓解(CR)率60.0％(15/25).初诊17例患者中,9例CR,4例部分缓解(PR);复发难治患者8例中,6例CR,1例PR.骨髓增生异常综合征(MDS)转化的AML7例中,5例CR,2例PR;≥50岁的11例患者中,8例CR,1例PR.化疗的不良反应主要为骨髓抑制、胃肠道反应、肝肾功能损害;无早期死亡病例.结论 IAG预激方案是治疗AML(包括高危AML)的较有效、安全的方案.
목적 탐토소제량아당포감화거갑양유홍매소연합립세포집락자격인자(G-CSF)조성적IAG예격방안치료급성수계백혈병(AML)적료효화환자불량반응.방법 회고성분석25례AML환자재채용IAG예격방안유도치료1개료정후적림상효과.IAG방안:거갑양유홍매소5 mg,정맥적주,격천1차,공7～8차;아당포감매12 h 10 mg/m2,피하주사,제1천지제14천;G-CSF매천200 μg/m2,피하주사,용약전일천지제14천.결과 화료후총유효솔80.0％(20/25),완전완해(CR)솔60.0％(15/25).초진17례환자중,9례CR,4례부분완해(PR);복발난치환자8례중,6례CR,1례PR.골수증생이상종합정(MDS)전화적AML7례중,5례CR,2례PR;≥50세적11례환자중,8례CR,1례PR.화료적불량반응주요위골수억제、위장도반응、간신공능손해;무조기사망병례.결론 IAG예격방안시치료AML(포괄고위AML)적교유효、안전적방안.
Objective To assess the therapeutic effect and side effects of IAG priming regimen for the treatment of acute myelogenous leukemia (AML).Methods A retrospective study of 25 AML patients receiving one course of IAG regimen treatment was performed.IAG priming regimen comprised low-dose cytarabine (10 mg/m2 subcutaneously every 12 h on days 1-14),idarubicin (5mg intravenously every other day for 7-8 times) and granulocyte colony-stimulating factor (200 mg/m2 subcutaneously daily on days 1-14).Results After one course induction therapy of IAG regimen,an overall response rate of 80 ％ (20/25) and complete remission rate of 60 ％ (15/25) were achieved.Among the initial diagnosed 17 AML patients,9 got CR,4 got PR.Among the 8 relapsed or refractory patients,6 got CR,1 got PR.Among the 7 AML patients transformed from myelodysplastic syndrome,5 got CR,2 got PR.Among the 11 aged patients (≥ 50 years old),8 achieved CR,1 achieved PR.The main side effects consisted of myelosuppression,gastrointestinal tract reaction and mild or moderate liver or renal impairment.No death was recorded.Conclusion IAG priming regimen is an effective and less toxic treatment protocol for AML patients,including those with high-risk features.